An Early Assessment of the Real-World Treatment Patterns of Type 2 Diabetes: A Comparison to the 2018 ADA/EASD Consensus Report Recommendations

• Published in: Diabetes therapy 2022-08, Vol.13 (8), p.1499-1510
• Main Authors: Bae, Jay P., Kadziola, Zbigniew A., Liu, Dongju, Chinthammit, Chanadda, Boye, Kristina S., Mather, Kieren J.
• Format: Article
• Language: English
• Subjects: Cardiology; Diabetes; Endocrinology; Hyperglycemia; Hypoglycemia; Internal Medicine; Medicare; Medicine; Medicine & Public Health; Obesity; Original Research; Patients
• ISSN: 1869-6953; 1869-6961
• DOI: 10.1007/s13300-022-01289-x

Introduction Using the American Diabetes Association (ADA) Hyperglycemic Pharmacotherapy Guidelines for type 2 diabetes, we evaluated the medication use patterns in real-world patients with type 2 diabetes in the USA. Methods Health care claims among patients with type 2 diabetes were analyzed (IBM ® MarketScan ® 2007 to 2019 Commercial and Medicare Databases). Diabetes treatment patterns were evaluated for the total patient sample of 580,741 during the year 2019. Prior years’ claims data were used to construct patient history and determine clinical groups per the 2018 ADA/EASD consensus statement: atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), heart failure (HF), hypoglycemia (hypo), and obesity. The recommended therapy use rates (RTUR) were calculated for clinical groups. Univariate chi-square tests were performed to compare RTUR within and outside clinical groups. Multivariate logistic regression was used to identify variables associated with recommended therapy use. Results A large proportion of patients belonged to multiple clinical groups; this was more common in the Medicare cohort. Each clinical group in the Commercial cohort had a substantially higher RTUR than in the Medicare cohort. However, no clinical group achieved > 40% RTUR. The RTUR was the highest in the CKD and obesity groups in the Commercial cohort and in the hypo and obesity groups in the Medicare cohort, but lowest in hypo and HF groups in the Commercial and Medicare cohorts, respectively. Conclusion Prevalence of guideline-aligned treatment use in 2019 was low, particularly since many patients fit into multiple risk groups with established treatment benefits.